Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates

Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii. Diazabicyclooctane (DBO) β-lactamase inhibitors, such as avibactam (AVI),...

詳細記述

書誌詳細

主要な著者:	Jose Cedano, Michelle Baez, Fernando Pasteran, Sabrina Daiana Montaña, Grace Ra, Venjaminne Fua, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramírez
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2022-07-01
シリーズ:	Frontiers in Cellular and Infection Microbiology
主題:	Acinetobacter carbapenem-resistance zidebactam sulbactam DBOs synergy
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.918868/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!